There were extraordinary scenes at the Scientific Sessions of the American Diabetes Association (ADA) in New Orleans earlier ...

Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.

By David Bautz, PhD NASDAQ: MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Multiple Presentations for DA-1726 and ...

Wider use of continuous glucose monitoring (CGM), glycemic management during cancer treatment, and individualized dosing of obesity drugs in people with diabetes are just a few of the new topics and ...

On the morning of June 5, 2026, attendees queued outside the main hall of the Ernest N. Morial Convention Center in New Orleans for the American Diabetes Association (ADA) Scientific Sessions. The ...

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve. In a VESALIUS-CV subgroup analysis, ...

Add Yahoo as a preferred source to see more of our stories on Google. Pharmaceutical Technology presents the obesity highlights from ADA 2026 As the 2026 American Diabetes Association (ADA) conference ...

Daewon Pharmaceutical will present key preclinical data on a next-generation quadruple-action obesity drug candidate at one ...

At the event, Novo Nordisk also announced that U.S. prescriptions for the pill-based version of Wegovy just hit 3 million.

Today I'm going to discuss the American Diabetes Association (ADA) 2026 Standards of Care. By way of full disclosure, I was part of the professional practice committee that created these guidelines, ...